CJC-1295 (5MG)

CJC-1295 — a long-acting GHRH (growth-hormone-releasing hormone) analog — supplied by BioFusion as a vacuum-sealed lyophilized 5mg vial for GHRH-pathway research chemistry.

Research context

CJC-1295 in the BioFusion catalog refers to the DAC-modified long-acting GHRH analog. The DAC (Drug Affinity Complex) modification — addition of a maleimidopropionyl group at the N-terminus — extends the research-half-life relative to the native 44-residue GHRH sequence. Compare with the unmodified CJC-1295 no DAC short-half-life form and the related Tesamorelin GHRH analog for full-class research panels.

Synthesis & documentation

Produced by solid-phase peptide synthesis using Fmoc protecting-group strategy in a U.S.-based ISO 9001:2008 facility, with the DAC modification incorporated post-synthesis. Each lot is verified for identity (LC-MS), purity (reverse-phase HPLC-UV ≥99.0%), moisture (Karl Fischer), and counter-ion (ion chromatography). Signed COA ships with every order. The Fmoc vs Boc primer covers the synthesis decision rationale.

Storage & handling

Lyophilized CJC-1295 is stable at −20 °C for the printed shelf life. After reconstitution, reference-stability data supports use within fourteen days at 2-8 °C protected from light; avoid freeze-thaw cycling. The BioFusion reconstitution calculator handles working-concentration math.

Why BioFusion

The DAC modification is technically demanding to synthesize at scale; under-modification or over-modification both produce off-spec batches. BioFusion verifies the modification stoichiometry by LC-MS at every release. Batch transparency ledger publishes synthesis-date and purity for every released lot. Bulk discounts at three+ vials; members save 25% on every order plus complimentary U.S. shipping for 365 days.

For research and laboratory use only. This product is not a drug, food, or cosmetic, and is not intended for diagnostic, therapeutic, or in vivo human use.